2020 journal article
Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy
JOURNAL OF VETERINARY INTERNAL MEDICINE, 34(6), 2211–2222.
author keywords: cardiac; cardiomyopathy; feline; hypertrophic; positive inotrope
MeSH headings : Animals; Cardiomyopathies / drug therapy; Cardiomyopathies / veterinary; Cardiotonic Agents / adverse effects; Cat Diseases / drug therapy; Cats; Heart Failure / drug therapy; Heart Failure / veterinary; Pyridazines / adverse effects; Retrospective Studies
TL;DR:
Pimobendan is well tolerated in cats with cardiomyopathy and CHF, regardless of the presence of OTO, and was discontinued due to adverse effects in 4/260 cats.
(via Semantic Scholar)
onlinelibrary.wiley.com (publisher PDF)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Source: Web Of Science
Added: October 26, 2020
Abstract